Description
NSI-189 Phosphate is a novel chemical entity with the systematic name (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone phosphate . It has a molecular formula of C22H30N4O·H3O4P and a molecular weight of 464.5 Da . NSI-189 was developed by Neuralstem, Inc. based on preclinical data demonstrating stimulation of neurogenesis in human hippocampus-derived neural stem cells in vitro and in mouse hippocampus in vivo . Unlike conventional antidepressants, NSI-189 is independent of monoamine reuptake pathways .
This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.
Key Research Focus
NSI-189 has been investigated in preclinical and clinical research exploring its roles in:
- Hippocampal Neurogenesis and Synaptic Plasticity: NSI-189 stimulates the generation of new neurons in the hippocampus, with regionally specific effects observed largely in the subventricular zone . In acute hippocampal slices, NSI-189 produces time- and dose-dependent increases in long-term potentiation (LTP) magnitude in the CA1 region, a cellular correlate of learning and memory .
- Antidepressant and Pro-Cognitive Effects: In a Phase 1B multiple-dose escalation study in depressed patients, NSI-189 was relatively well tolerated and showed potential for mitigating depressive symptoms while concurrently improving cognitive function . A Phase 2 double-blind, placebo-controlled study in outpatients with major depressive disorder (MDD) evaluated oral NSI-189 as monotherapy, with findings replicating those of the Phase 1B study and warranting further exploration . A post-hoc analysis suggested NSI-189 selectively benefits moderately depressed patients .
- Angelman Syndrome (Preclinical Model): In a mouse model of Angelman Syndrome, daily injections of NSI-189 reversed impairments in cognitive and motor functions, with effects associated with activation of the TrkB and Akt signaling pathways . The study concluded that NSI-189 could represent a potential treatment for Angelman Syndrome patients .
- Diabetic Neuropathy and Mitochondrial Function: NSI-189 enhanced mitochondrial function and reversed peripheral neuropathy and memory impairment in a rat model of type 2 diabetes . Additional research demonstrated amelioration of both central and peripheral neuropathy in mouse models of type 1 and type 2 diabetes .
- Radiation-Induced Cognitive Dysfunction: Oral administration of NSI-189 demonstrated neuroprotective effects in remediation of radiation-induced cognitive dysfunction in preclinical models .
Clinical Development Status
NSI-189 has completed Phase 1 and Phase 2 clinical trials for major depressive disorder. A Phase 2 trial (NCT02695472) evaluated NSI-189 at 40 mg once daily and 80 mg/day (40 mg twice daily) over 12 weeks in approximately 220 subjects . The drug has also received FDA Orphan Drug Designation (647018) . Clinical trial locations were concentrated in the United States, with Neuralstem Inc. as the primary sponsor .
Product Specifications
- Form: Lyophilized Powder (Sterile)
- Purity: ≥95% (HPLC Verified)
- Molecular Formula: C22H30N4O·H3O4P
- Molecular Weight: 464.50 Da
- CAS Number: 1270138-41-4
- Storage: Store at -20°C (freezer) for long-term stability. Protect from light.
- Solubility: Soluble in sterile water or buffer for laboratory use.
- Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use.
Why Choose NSI-189 Phosphate?
NSI-189 Phosphate offers a mechanistically distinct research tool for studying hippocampal neurogenesis and synaptic plasticity, operating independently of traditional monoamine pathways . Its demonstrated effects on LTP enhancement, TrkB/Akt pathway activation, and cognitive function reversal in Angelman Syndrome models provide defined molecular targets for experimental design . The availability of Phase 1B and Phase 2 clinical data in MDD offers a translational foundation, and the FDA Orphan Drug Designation supports its research relevance for rare cognitive disorders . Researchers should note that the exact molecular target remains unknown, though the neurogenic mechanism is well-characterized




